NCT04370548 - DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) | Biotech Hunter

Enrollment

307

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

December 7, 2020

Conditions

Bacterial Vaginosis

Interventions

DRUG

DARE-BV1clindamycin phosphate vaginal gel, 2%

One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.

Trial Locations (10)

23507

Eastern Virginia Medical School, Norfolk

30044

NuDirections Clinical Research, Inc., Lawrenceville

33186

New Age Medical Research Corporation, Miami

33351

Precision Clinical Research, LLC, Sunrise

33409

Comprehensive Clinical Trials, LLC, West Palm Beach

38305

The Jackson Clinic, PA, Jackson

80209

Downtown Women's Health Care, Denver

85712

Vision Clinical Research-Tuscon, Tucson

08648

Capital Health-Lawrence OB/GYN, Lawrenceville

08684

The Center for Women's Health & Wellness, LLC, Lawrenceville